A groundbreaking first-in-human clinical trial has shown promising results for a new treatment targeting retinitis pigmentosa, a leading cause of inherited blindness. Researchers found that a photoswitch molecule injected into the eye reactivated damaged retinal cells, allowing them to respond to light even after normal light-sensing cells were lost. The treatment was well tolerated, with no serious side effects, and some participants experienced improved light perception and better performance in visual tasks. Unlike gene therapies, this approach could work across multiple forms of retinal degeneration without genetic modification. While the findings are preliminary, a larger Phase 2 trial is already underway to evaluate its effectiveness.
Read more at NewsMedical